Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17875941 | 0.96 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17876000 | 0.95 | KMT2A (0.45) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17875943 | 0.94 | PLA2G2A (0.41) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17875960 | 0.94 | PLA2G2A (0.41) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17875933 | 0.92 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17875949 | 0.92 | HSP90AA1 (0.35) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17875942 | 0.92 | HSP90AA1 (0.35) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17875924 | 0.91 | ALOX5 (0.46) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17875939 | 0.91 | ALOX5 (0.46) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17875995 | 0.91 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10581000-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-03-03 | — | — | US | disclosed |
| US-20160190482-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160190482-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10581000-B2 | Condensed cyclic compound and organic light-emitting device including the same | CRY1, CRY2, CCNE2 | MEN1 448/4885KMT2A 1757/4885SMN1; SMN2 3237/4885 |
| US-20160190482-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNE2 | MEN1 448/4885KMT2A 1757/4885SMN1; SMN2 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.